Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2023-09-25 Legal Proceedings Report
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Legal Proceedings Report 2023
Legal Proceedings Report Classification · 99% confidence The document is a short announcement (3288 characters) dated September 25, 2023, titled "Status of the Company's receivables from Portinho S.A." It discusses the status of a receivable, potential delays, security provided to creditors, and the exploration of bridge financing. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER) focusing on period results. It is a specific, material update regarding a significant financial/capital matter (receivables and potential financing). This fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS) if no other category fits. Since it explicitly mentions looking into 'possible bridge financing' due to a payment postponement, CAP is the most specific fit for this type of corporate finance news.
2023-09-25 English
Legal Proceedings Report 2023
Legal Proceedings Report Classification · 99% confidence The document is a formal announcement titled "Status for Selskabets tilgodehavende fra Portinho S.A." (Status for the Company's receivable from Portinho S.A.). It discusses the valuation of a receivable, dialogue with the counterparty, security given to creditors, and the pursuit of bridge financing due to payment delays. This content relates to the company's financial position, capital structure, and debt management, but it is not a full annual report (10-K), an interim report (IR), or a standard earnings release (ER). It specifically mentions working on 'bridge financing' and details security arrangements over an asset, which strongly suggests an update related to financing activities or capital structure changes. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate classification for an announcement detailing efforts to secure short-term funding due to a delayed receivable payment.
2023-09-25 Danish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Consolidated interim report 1 January – 30 June 2023' and contains substantive financial data, including a financial summary, loss after tax, equity figures, and outlook. Although it includes a link to an attachment at the end, the text itself provides the core content of the interim report, making it a primary financial document rather than just an announcement. Therefore, it is classified as an Interim/Quarterly Report. H1 2023
2023-08-16 English
Consolidated interim report 1 January – 30 June 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Consolidated interim report' for the 6-month period ended 30 June 2023. It contains detailed financial statements, including the consolidated statement of comprehensive income, statement of financial position, and cash flow statement, along with management's review and notes. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2023
2023-08-16 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a short announcement (3524 characters) issued by Pharma Equity Group A/S (Selskabsmeddelelse nr. 37) regarding its subsidiary receiving a 'Notice of Allowance' from the USPTO for a patent application related to a wound-healing drug combination. This is a specific corporate event announcement concerning intellectual property and regulatory progress, not a full financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since it is a specific regulatory/legal development announcement that doesn't fit perfectly into the other specific categories (like DIRS, LTR, or CAP), and it is a formal company announcement, the most appropriate general category for specific, non-financial corporate news that isn't a standard report is 'Regulatory Filings' (RNS), as it details a regulatory/legal milestone (patent allowance). However, given the context of patent issuance, it is a specific corporate action announcement. Since there is no specific 'Intellectual Property' or 'Patent Update' code, and it is not a legal proceeding (LTR), RNS serves as the best fit for a specific, non-financial regulatory update that is not a report itself.
2023-08-15 Danish
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a short announcement (3498 characters) dated August 15, 2023, titled 'Announcement no. 37'. It details a specific corporate event: a subsidiary receiving a Notice of Allowance from the USPTO for a patent. This is not a full financial report (like 10-K or IR), nor is it a management change (MANG), dividend notice (DIV), or earnings release (ER). It is a specific, material corporate update that does not fit neatly into the primary financial reporting categories. Since it is a general regulatory/corporate update that doesn't match a more specific category like DIRS, DVA, or CAP, it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous corporate announcement, or potentially LTR if viewed as a legal/IP update, but RNS is the broader fallback for non-financial material news.
2023-08-15 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.